RXRX — RECURSION PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1601830 ·
Last close
$2.72
Market Cap
$1.69B
52W High
$5.24
52W Low
$2.50
ADV30
25,038,091
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 18,055,000 | 8,010,000 | -123,176,000 | -119,036,000 | 1,221,712,000 | 549,853,000 | 315,900,000 |
| Jun 2026 | 7,303,000 | -4,188,000 | -134,968,000 | -131,005,000 | 1,212,668,000 | 545,683,000 | 297,665,000 |
| Mar 2026 | 6,301,000 | -6,189,000 | -128,505,000 | -117,504,000 | 1,339,522,000 | 654,473,000 | 314,753,000 |
| Dec 2025 | 35,351,000 | 21,076,000 | -108,334,000 | -108,122,000 | 1,474,130,000 | 743,294,000 | 343,265,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-310,527,000
Investing CF
$-3,948,000
Financing CF
$210,413,000
CapEx
$-3,948,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.90
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,443,547,000
Inventory
—
Receivables
$34,065,000
ST Investments
—
EBIT TTM
$-479,312,000
Pretax Income TTM
$-480,226,000
Interest Exp TTM
$914,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$68,232,000
EBITDA
$-427,084,992
Free Cash Flow
$-203,124,496
Enterprise Value
$1,719,101,824
Total Cash
$549,852,992
Total Debt
$74,700,000
Shares Out
622,759,259
Trailing EPS
$-0.86
Book Value
$1.61
ROE
-48.7%
ROA
-23.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 74,256,000 | -648,132,000 | -644,759,000 | 1,474,130,000 | 343,265,000 | 1,130,865,000 | -371,808,000 |
| Dec 2024 | 58,488,000 | -479,004,000 | -463,661,000 | 1,448,598,000 | 413,816,000 | 1,034,782,000 | -359,174,000 |
| Dec 2023 | 43,876,000 | -350,060,000 | -328,066,000 | 653,699,000 | 190,263,000 | 463,436,000 | -287,780,000 |
| Dec 2022 | 39,681,000 | -245,727,000 | -239,476,000 | 701,288,000 | 215,482,000 | 485,806,000 | -83,524,000 |
TTM Snapshot
Revenues TTM
$54,855,000
NetIncome TTM
$-518,884,000
OpCashFlow TTM
—
Assets (Latest)
$1,212,668,000
Forward EPS
$-0.85
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $3.00 · spot: $2.83 · call volume: 1,117 · put volume: 261
Expected Move to 2027-01-15:
±$0.81
(28.67%) —
implied range
$2.02 –
$3.64
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LYCA | Lycia Therapeutics, Inc. | $1.61B | $30.92 | — |
| MAZE | Maze Therapeutics, Inc. | $1.80B | $32.87 | — |
| VIR | Vir Biotechnology, Inc. | $1.58B | $9.25 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $1.83B | $39.06 | — |
| ALVO | Alvotech | $1.56B | $4.37 | — |
News headlines (Yahoo Finance, 1h cache)
Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design
2026-11-18 22:40 · Yahoo
Why Recursion Pharmaceuticals Stock Is Up Today
2026-11-18 17:23 · Yahoo
What Recursion Pharmaceuticals Investors Missed Before The Fall
2026-11-18 04:34 · Yahoo
Recursion to Participate in Upcoming Investor Conferences
2026-11-11 13:00 · Yahoo
Recursion Pharmaceuticals Inc (RXRX) Q3 2026 Earnings Call Highlights: Durable FAP Data, Early ...
2026-11-11 01:07 · Yahoo
AI in Predictive Toxicology - Global Strategic Business Report 2026: Capture a $3.2 Billion Market by 2032 as BenevolentAI, Insilico Medicine, Recursion Pharmaceuticals and Revvity Disrupt Testing
2026-11-09 15:14 · Yahoo
Is Recursion Pharmaceuticals (RXRX) A Bargain After Q3 Earnings And Clinical Updates?
2026-11-05 08:16 · Yahoo
REC 4881 Trial Results Could Change The Case For Recursion Pharmaceuticals Stock
2026-11-05 00:15 · Yahoo
Recursion Pharmaceuticals (RXRX) Puts Fred Hassan In The Chair After Phase 2 Win
2026-11-04 22:15 · Yahoo
RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway
2026-11-04 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.